The system, which uses Dune’s proprietary tissue characterization technology, provides surgeons and radiologists with the real time ability to identify cancerous tissues.

Agaplesion Markus Hospital breast cancer center and gynecology and obstetrics department head Marc Thill said, " I believe that this technology represents a real breakthrough for breast conserving surgery."

Dune Medical Devices chief executive officer Dan Levangie said by reducing the chances of going back for multiple surgeries, the MarginProbe system can improve patients’ experiences being treated for breast cancer.

"We are excited to continue to work with Dr. Thill at Agaplesion Markus Hospital," Levangie added.

The company said MarginProbe is an investigational device and is not available for sale in the U.S.